Elenae Therapeutics, Inc.

About

Elenae Therapeutics, Inc. is a platform RNA Medicine company with cutting-edge AI-designed antisense oligonucleotide (ASO) technology that can target and penetrate tissues not previously thought accessible to ASOs, including heart, skeletal muscle, retina, and lung, with an excellent safety profile. Elenae is initially targeting microRNAs identified as major pathological contributors to several aging-related diseases that limit healthspan (heart failure, dry age-related macular degeneration (AMD), and aging-related sarcopenia), as well as rare diseases such as Duchenne and Becker muscular dystrophies. The modality is based on locked nucleic acid (LNA) ASO mixmers with a phosphorothioate (PS) backbone, delivered once-weekly to once-monthly subcutaneously in saline. There is strong efficacy and safety data in mice, pigs and/or NHPs for all indications. Elenae was founded in 2021 by Anders M. Näär, PhD, Professor of Metabolic Biology at University of California, Berkeley. Elenae is housed in the Bakar Labs biotech incubator next to the UC Berkeley campus. Prof. Näär is on leave of absence and serving as full time CEO, and an ASO drug development team is in place.

Product

Value proposition

AI-guided design of steric-blocking LNA ASO mixmers for disease-driving RNA biology with extrahepatic pharmacology, enabling targetable RNA medicine campaigns and partner-ready programs

Target customers

Biotech and pharmaceutical companies seeking RNA-targeted therapeutics; potential research partners

Founders

• Anders M. Näär — Founder & CEO
• Sakari Kauppinen — Founder

Categories

Products

Key features

Technologies

Integrations

Target conditions

Care settings

Partnerships

Traction metrics

Investors

News

• Companies - Bakar Bio Labs · 2025-09-04T00:00:00.000Z
• Anders Naar posted this - LinkedIn · 2026-01-09T00:00:00.000Z
• Elegen and Nutcracker Therapeutics to Pilot First Fully Cell-Free Manufacturing Process for RNA-based Personalized Cancer Therapeutics · 2025-07-12T10:54:05.000Z
• Eilean Therapeutics Presents Novel, Selective, Brain-Permeable CDK2 Inhibitor for Treatment of CCNE1-Dependent Cancers — Eilean Therapeutics · 2025-10-16T12:00:00.000Z
• About Eliaz Therapeutics - Eliaz Therapeutics · 2026-05-14T14:03:19.000Z
• EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Conference — Eilean Therapeutics · 2025-10-13T19:49:18.000Z

Browse similar startups

Related startups

• Elomia Health — San Francisco, CA
• Emerald Care Home — Dublin, CA
• Endo Health (a16z SR) — San Francisco, CA
• Evercrisp Biosciences — Berkeley, CA
• EXCEL MEDICAL BILLING, INC. — Los Angeles, CA
• Eye On Vision Optometry — Palo Alto, CA
• Elevare Law — Richmond, VA
• Elevate Vision Care — Katy, TX
• Elite Diagnostics — Crown Point, IN
• EliVive — Portland, ME
• Elm Biosciences — New York, NY
• EM Nutrition - Group Dietitian Practice — New York, NY